Inspire Medical Systems Q4 revenue beats estimates

Inspire Medical Systems

11/02/2026 21:10

Overview

Medical technology firm's Q4 revenue rose 12%, beating analyst expectations

Adjusted EPS for Q4 was $1.65

Company repurchased $50 mln in shares during Q4

Outlook

Company revises 2026 revenue outlook to $950 mln-$1 bln, reflecting 4%-10% growth

Inspire expects 2026 adjusted operating margin between 6% and 8%

Company anticipates 2026 adjusted EPS between $1.85 and $2.35

Result Drivers

INSPIRE V SYSTEM - Revenue growth driven by increased sales volume and favorable sales mix of Inspire V system

MARKETING INVESTMENTS - Operating expenses increased due to higher investments in patient marketing and education

REIMBURSEMENT CLARITY - Company received clarification on coding for Inspire V procedure, impacting reimbursement strategy

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$269.10 mln
$265.67 mln (17 Analysts)
Q4 EPS
$4.66
Q4 Net Income
$136.10 mln
Q4 Revenue Growth
12.00%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Inspire Medical Systems Inc is $130.00, about 90.8% above its February 10 closing price of $68.14

The stock recently traded at 39 times the next 12-month earnings vs. a P/E of 51 three months ago

Press Release: ID:nGNX16bbtg

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)